{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:24:43Z","timestamp":1770747883889,"version":"3.49.0"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science, and Technology of Japan","doi-asserted-by":"crossref","award":["20K17467"],"award-info":[{"award-number":["20K17467"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Optimal cefepime dosing is a challenge because of its dose-dependent neurotoxicity. This study aimed to determine individualized cefepime dosing for febrile neutropenia in patients with lymphoma or multiple myeloma.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This prospective study enrolled 16 patients receiving cefepime at a dose of 2 g every 12 hours. Unbound concentrations were determined at 0.5 hours, 7.2 hours [at the 60% time point of the 12 hours administration interval (C7.2h)], and 11 hours (trough concentration) after the first infusion (rate: 2 g\/h). The primary and secondary end points were the predictive performance of the area under the unbound concentration\u2013time curve (AUC<jats:sub>unbound<\/jats:sub>) and the effect of unbound cefepime pharmacokinetic parameters on clinical response, respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The mean (SD) AUC<jats:sub>unbound<\/jats:sub> was 689.7 (226.6) mcg h\/mL, which correlated with C7.2h (R<jats:sup>2<\/jats:sup> = 0.90), and the Bayesian posterior AUC<jats:sub>unbound<\/jats:sub> using only the trough concentration (R<jats:sup>2<\/jats:sup> = 0.66). Although higher exposure was more likely to show a better clinical response, each parameter did not indicate a statistical significance between positive and negative clinical responses (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.0907 for creatinine clearance (Ccr), 0.2523 for C7.2h, 0.4079 for trough concentration, and 0.1142 for AUC<jats:sub>unbound<\/jats:sub>). Cutoff values were calculated as 80.2 mL\/min for Ccr (sensitivity: 0.889, specificity: 0.714), 18.6 mcg\/mL for C7.2h (sensitivity: 0.571, specificity: 1.000), and 9.2 mcg\/mL for trough concentration (sensitivity: 0.571, specificity: 1.000). When aiming for a time above 100% the minimum inhibitory concentration, both continuous infusion of 4 g\/d and intermittent infusion of 2 g every 8 hours achieved a probability of approximately 100% at a minimum inhibitory concentration of 8 mcg\/mL.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Therapeutic drug monitoring by sampling at C7.2h or trough can facilitate rapid dose optimization. Continuous infusion of 4 g\/d was recommended. Intermittent dosing of 2 g every 8 hours was alternatively suggested for patients with a Ccr of 60\u201390 mL\/min.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001138","type":"journal-article","created":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T04:00:52Z","timestamp":1695355252000},"page":"80-88","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Dose Individualization of Cefepime for Febrile Neutropenia in Patients With Lymphoma or Multiple Myeloma: Implications for Therapeutic Drug Monitoring"],"prefix":"10.1097","volume":"46","author":[{"given":"Kazutaka","family":"Oda","sequence":"first","affiliation":[{"name":"Pharmacy and"},{"name":"Infection Control, Kumamoto University Hospital, Chuo-ku, Kumamoto, Japan; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayami","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Kumamoto University, Chuo-ku, Kumamoto, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoya","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Kumamoto University, Chuo-ku, Kumamoto, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotomo","family":"Nakata","sequence":"additional","affiliation":[{"name":"Infection Control, Kumamoto University Hospital, Chuo-ku, Kumamoto, Japan; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Higuchi","sequence":"additional","affiliation":[{"name":"Infection Control, Kumamoto University Hospital, Chuo-ku, Kumamoto, Japan; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kisato","family":"Nosaka","sequence":"additional","affiliation":[{"name":"Infection Control, Kumamoto University Hospital, Chuo-ku, Kumamoto, Japan; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Jono","sequence":"additional","affiliation":[{"name":"Pharmacy and"},{"name":"Department of Clinical Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Kumamoto University, Chuo-ku, Kumamoto, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Saito","sequence":"additional","affiliation":[{"name":"Pharmacy and"},{"name":"Department of Clinical Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Kumamoto University, Chuo-ku, Kumamoto, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,9,18]]},"reference":[{"key":"R1-20250603","first-page":"369","article-title":"Cefepime: the next generation?","volume":"17","author":"Sanders","year":"1993","journal-title":"Clin Infect Dis."},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis."},{"issue":"suppl 2","key":"R3-20250603","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1016\/j.ijantimicag.2005.08.001","article-title":"Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group","volume":"26","author":"Tamura","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1200\/JCO.2017.77.6211","article-title":"Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update","volume":"36","author":"Taplitz","year":"2018","journal-title":"J Clin Oncol."},{"issue":"suppl 5","key":"R5-20250603","doi-asserted-by":"crossref","first-page":"v252","DOI":"10.1093\/annonc\/mdq196","article-title":"Management of febrile neutropenia: ESMO clinical practice guidelines","volume":"21","author":"de Naurois","year":"2010","journal-title":"Ann Oncol."},{"key":"R6-20250603","first-page":"20499361221138346","article-title":"Approach to fever in patients with neutropenia: a review of diagnosis and management","volume":"9","author":"Keck","year":"2022","journal-title":"Ther Adv Infect Dis."},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.3324\/haematol.2013.091025","article-title":"European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia","volume":"98","author":"Averbuch","year":"2013","journal-title":"Haematologica"},{"issue":"suppl 5","key":"R8-20250603","doi-asserted-by":"crossref","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","article-title":"Management of febrile neutropaenia: ESMO clinical practice guidelines","volume":"27","author":"Klastersky","year":"2016","journal-title":"Ann Oncol."},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"882","DOI":"10.6004\/jnccn.2016.0093","article-title":"Prevention and treatment of cancer-related infections, version 2.2016, NCCN clinical practice guidelines in oncology","volume":"14","author":"Baden","year":"2016","journal-title":"J Natl Compr Canc Netw."},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/infdis\/162.4.981","article-title":"Beta-lactam-resistant Enterobacter bacteremia in febrile neutropenic patients receiving monotherapy","volume":"162","author":"Johnson","year":"1990","journal-title":"J Infect Dis."},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1086\/655131","article-title":"Meta-analysis of a possible signal of increased mortality associated with cefepime use","volume":"51","author":"Kim","year":"2010","journal-title":"Clin Infect Dis."},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jiac.2016.01.005","article-title":"The efficacy and safety of cefepime or meropenem in the treatment of febrile neutropenia in patients with lung cancer. A randomized phase II study","volume":"22","author":"Fujita","year":"2016","journal-title":"J Infect Chemother."},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.cmi.2017.03.024","article-title":"Comparison of antipseudomonal \u03b2-lactams for febrile neutropenia empiric therapy: systematic review and network meta-analysis","volume":"23","author":"Horita","year":"2017","journal-title":"Clin Microbiol Infect."},{"key":"R14-20250603","first-page":"CD005197","article-title":"Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams","volume":"2010","author":"Paul","year":"2010","journal-title":"Cochrane Database Syst Rev."},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/jac\/dki448","article-title":"Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials","volume":"57","author":"Paul","year":"2006","journal-title":"J Antimicrob Chemother."},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"ofx113","DOI":"10.1093\/ofid\/ofx113","article-title":"The dose-dependent efficacy of cefepime in the empiric management of febrile neutropenia: a systematic review and meta-analysis","volume":"4","author":"Andreatos","year":"2017","journal-title":"Open Forum Infect Dis."},{"key":"R17-20250603","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.ARBA-0009-2017","article-title":"Antimicrobial resistance: a one health perspective","volume":"6","author":"McEwen","year":"2018","journal-title":"Microbiol Spectr."},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1177\/10781552221080078","article-title":"Smaller but more frequent dosing of cefepime in the treatment of febrile neutropenia","volume":"28","author":"Okubo","year":"2022","journal-title":"J Oncol Pharm Pract."},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1128\/AAC.00389-15","article-title":"Adequacy of high-dose cefepime regimen in febrile neutropenic patients with hematological malignancies","volume":"59","author":"Sime","year":"2015","journal-title":"Antimicrob Agents Chemother."},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/phar.1807","article-title":"Pharmacokinetics of cefepime in patients with cancer and febrile neutropenia in the setting of hematologic malignancies or hematopoeitic cell transplantation","volume":"36","author":"Whited","year":"2016","journal-title":"Pharmacotherapy"},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"R51","DOI":"10.1186\/cc8941","article-title":"Prospective monitoring of cefepime in intensive care unit adult patients","volume":"14","author":"Chapuis","year":"2010","journal-title":"Crit Care"},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1128\/AAC.01141-08","article-title":"Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia","volume":"53","author":"Nicasio","year":"2009","journal-title":"Antimicrob Agents Chemother."},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.ijantimicag.2017.04.008","article-title":"Population pharmacokinetics of cefepime in febrile neutropenia: implications for dose-dependent susceptibility and contemporary dosing regimens","volume":"50","author":"Rhodes","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"e00745-20","DOI":"10.1128\/AAC.00745-20","article-title":"Population pharmacokinetics and target attainment of cefepime in critically ill patients and guidance for initial dosing","volume":"64","author":"Al-Shaer","year":"2020","journal-title":"Antimicrob Agents Chemother."},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/jcph.1967","article-title":"Evaluation of individualized cefepime dosing strategy using population pharmacokinetics","volume":"62","author":"Mo","year":"2022","journal-title":"J Clin Pharmacol."},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3947\/ic.2022.0087","article-title":"Population pharmacokinetics and Monte Carlo simulation of cefepime in critically ill patients with hospital-acquired\/ventilator-associated pneumonia","volume":"55","author":"Seo","year":"2023","journal-title":"Infect Chemother."},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.2147\/IDR.S213183","article-title":"Augmented renal clearance is associated with inadequate antibiotic pharmacokinetic\/pharmacodynamic target in Asian ICU population: a prospective observational study","volume":"12","author":"Wu","year":"2019","journal-title":"Infect Drug Resist."},{"key":"R28-20250603","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1248\/yakushi.16-00168","article-title":"[Relationship between PK\/PD of cefepime and clinical outcome in febrile neutropenic patients with normal renal function]","volume":"136","author":"Yamashita","year":"2016","journal-title":"Yakugaku Zasshi"},{"key":"R29-20250603","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ijantimicag.2007.04.012","article-title":"Pharmacokinetic and pharmacodynamic profiling of cefepime in plasma and peritoneal fluid of abdominal surgery patients","volume":"30","author":"Ikawa","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"R30-20250603","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1093\/jac\/dkac271","article-title":"Cefepime-induced neurotoxicity: systematic review","volume":"77","author":"Maan","year":"2022","journal-title":"J Antimicrob Chemother."},{"key":"R31-20250603","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s13054-017-1856-1","article-title":"Cefepime-induced neurotoxicity: a systematic review","volume":"21","author":"Payne","year":"2017","journal-title":"Crit Care"},{"key":"R32-20250603","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/BF01709751","article-title":"The SOFA (Sepsis-related organ failure assessment) score to describe organ dysfunction\/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine","volume":"22","author":"Vincent","year":"1996","journal-title":"Intensive Care Med."},{"key":"R33-20250603","first-page":"302","article-title":"Adjustment of cefepime dosage in patients with renal impairment","volume":"53","author":"Yoshitsugu","year":"2005","journal-title":"Jpn J Chemother."},{"key":"R34-20250603","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"R35-20250603","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1128\/AAC.27.2.207","article-title":"Comparison of a new cephalosporin, BMY 28142, with other broad-spectrum beta-lactam antibiotics","volume":"27","author":"Kessler","year":"1985","journal-title":"Antimicrob Agents Chemother."},{"key":"R36-20250603","doi-asserted-by":"crossref","first-page":"dlac043","DOI":"10.1093\/jacamr\/dlac043","article-title":"Therapeutic drug monitoring of cefepime in a non-critically ill population: retrospective assessment and potential role for model-based dosing","volume":"4","author":"Suttels","year":"2022","journal-title":"JAC Antimicrob Resist."},{"key":"R37-20250603","doi-asserted-by":"crossref","first-page":"e0204621","DOI":"10.1128\/aac.02046-21","article-title":"Cefepime precision dosing tool: from standard to precise dose using nonparametric population pharmacokinetics","volume":"66","author":"Alshaer","year":"2022","journal-title":"Antimicrob Agents Chemother."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001138","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:06:10Z","timestamp":1748970370000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,18]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001138","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,18]]},"assertion":[{"value":"2023-05-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-22","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}